FDA Warns Enessa For Claims Violations, Diminish-Rosacea Treatment
This article was originally published in The Rose Sheet
Executive Summary
Natural brand Enessa may have to discontinue or relabel its Diminish-Rosacea Treatment, as the name constitutes an unapproved drug claim, FDA suggests in a warning letter. Other claims cited by the agency pertain to cellular repair, collagen synthesis, anti-inflammatory benefits and improved micro-circulation.